Literature DB >> 22795997

Duration of well-controlled core temperature correlates with neurological outcome in patients with post-cardiac arrest syndrome.

Koichiro Shinozaki1, Shigeto Oda, Tomohito Sadahiro, Masataka Nakamura, Yo Hirayama, Eizo Watanabe, Yoshihisa Tateishi, Kasuya Nakanishi, Nobuya Kitamura, Hiroyuki Hirasawa.   

Abstract

PURPOSE: Detailed procedures for optimal therapeutic hypothermia (TH) have yet to be established. We examined how duration of well-controlled core temperature within the first 24 hours after cardiac arrests (CA) correlated with neurological outcomes of successfully resuscitated out-of-hospital CA (OHCA) patients.
METHODS: OHCA patients who survived over 24 hours and treated with TH were included. Core temperature was measured every hour. Physicians intended to maintain temperature at 33 °C ± 1 °C for 24 hours. Cerebral performance categories (CPC) of patients at 6 months were recorded and patients were retrospectively divided into favorable (CPC1,2) and poor (CPC3-5) neurological outcome groups. Total time while the core temperature reached to 33 °C ± 1 °C within the first 24 hours after CA was measured and this duration was defined that of well-controlled temperature. receiver-operating characteristic analysis was performed on duration of well-controlled temperature to select the optimal cutoff value. Neurological outcome predictors were investigated by logistic regression analysis.
RESULTS: Fifty-six patients were included. Optimal cutoff value of duration of well-controlled temperature was 18 hours. Ratio of male sex, witnessed by emergency medical service (EMS) personnel, first electrocardiogram as shockable, and duration of well-controlled core temperature ≥ 18 h of favorable neurological outcome group (n = 21) were significantly larger than that of poor neurological outcome group (n = 35). Logistic regression analysis identified "witnessed by EMS", "performed bystander CPR," and "the duration ≥ 18 h" as independent predictors of favorable neurological outcome.
CONCLUSION: TH maintained at target temperature of 33 °C ± 1 °C over 18 hours independently correlated with favorable neurological outcome. Therefore, stable core temperature control may improve neurological outcome of successfully resuscitated OHCA.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22795997     DOI: 10.1016/j.ajem.2012.03.024

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

Review 1.  The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society.

Authors:  Lori Kennedy Madden; Michelle Hill; Teresa L May; Theresa Human; Mary McKenna Guanci; Judith Jacobi; Melissa V Moreda; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

Review 2.  Targeted temperature management and early neuro-prognostication after cardiac arrest.

Authors:  Songyu Chen; Brittany Bolduc Lachance; Liang Gao; Xiaofeng Jia
Journal:  J Cereb Blood Flow Metab       Date:  2021-01-14       Impact factor: 6.200

3.  Intravascular Versus Surface Cooling in Patients Resuscitated From Cardiac Arrest: A Systematic Review and Network Meta-Analysis With Focus on Temperature Feedback.

Authors:  Nikolai Ramadanov; Jasmin Arrich; Roman Klein; Harald Herkner; Wilhelm Behringer
Journal:  Crit Care Med       Date:  2022-01-31       Impact factor: 9.296

4.  Cardiac arrest survivors treated with or without mild therapeutic hypothermia: performance status and quality of life assessment.

Authors:  Robert Kowalik; Ewa Szczerba; Łukasz Kołtowski; Marcin Grabowski; Karolina Chojnacka; Wojciech Golecki; Adam Hołubek; Grzegorz Opolski
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-12-12       Impact factor: 2.953

5.  Outcome and current status of therapeutic hypothermia after out-of-hospital cardiac arrest in Korea using data from the Korea Hypothermia Network registry.

Authors:  Byung Kook Lee; Kyu Nam Park; Gu Hyun Kang; Kyung Hwan Kim; Giwoon Kim; Won Young Kim; Jin Hong Min; Yooseok Park; Jung Bae Park; Gil Joon Suh; Yoo Dong Son; Jonghwan Shin; Joo Suk Oh; Yeon Ho You; Dong Hoon Lee; Jong Seok Lee; Hoon Lim; Tae Chang Jang; Gyu Chong Cho; In Soo Cho; Kyoung Chul Cha; Seung Pill Choi; Wook Jin Choi; Chul Han
Journal:  Clin Exp Emerg Med       Date:  2014-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.